Expert perspectives on comprehensive treatment strategies for metastatic colorectal cancer, including systemic therapies, precision medicine, and the potential for cure.
Updated Zanidatamab Data Shows Durable Response in Biliary Tract Cancer
Shubham Pant, MD, MBBS, discussed the use of zanidatamab and the HERIZON-BTC-01 trial in HER2-positive biliary tract cancer treatment.
Read More
LaPelusa’s Journey in the Dynamic Field of GI Oncology
In this episode of Emerging Experts, Michael LaPelusa, MD, shares his insights, experiences, and passion for cancer research, particularly in the realm of gastrointestinal cancers.
Listen
Adding Bevacizumab Improves PFS, But Not OS, in Advanced Biliary Tract Cancer
Bevacizumab in combination with atezolizumab and chemotherapy led to improvements in progression-free survival and duration of response in patients with advanced biliary tract cancer.
Unpacking the Latest Research in Gastrointestinal Cancers
In season 4, episode 1 of Targeted Talks, Benjamin L. Schlechter, MD, discuses new studies in the gastrointestinal cancers space.
Lenvatinib/Pembrolizumab/TACE Regimen Improves PFS in Intermediate-Stage HCC
Josep M. Llovet, MD, PhD, discussed the updated data from the LEAP-012 trial in intermediate-stage hepatocellular carcinoma.
Zolbetuximab Scores FDA Approval in CLDN 18.2+ Gastric/GEJ Cancer
This approval marks the first CLDN 18.2-targeted therapy in this patient population.